Format

Send to

Choose Destination
Eur J Surg Oncol. 2003 Apr;29(3):278-83.

The management of benign and malignant pheochromocytoma and abdominal paraganglioma.

Author information

1
Department of Surgery, Karolinska Hospital, SE-171 76, Stockholm, Sweden. Elisabeth.Edstrom-Elder@ks.se

Abstract

AIMS:

To report treatment and outcome in patients with malignant and benign pheochromocytoma and abdominal paraganglioma.

METHODS:

Review of clinical and therapeutic features in 85 patients with pheochromocytoma or abdominal paraganglioma between 1976 and 1999.

RESULTS:

Thirty-nine of 85 patients presented with symptoms other than classical paroxysmal attacks. Paragangliomas were more often malignant (7/15) than pheochromocytomas (7/70). No recurrences have occurred in 71 patients with tumours initially classified as benign after a median follow-up time of 144 months (range 7-287). Nine of 14 patients with tumours classified as malignant have developed metastasis and/or local recurrence. Treatment of malignant tumours with cyclophosphamide, vincristine and dacarbazine (CVD) improved or stabilised the disease in three of four patients.

CONCLUSION:

Life long follow-up of patients with benign pheochromocytoma is not necessary. Combination chemotherapy (CVD) is a valid option in the treatment of malignant pheochromocytomas and abdominal paragangliomas.

PMID:
12657240
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center